RVMD Q4 2019 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+16.8% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$20M-161.8% margin

Net Income

-$15M-120.7% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-3.3%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$221M

Total Liabilities

$68M

Stockholders' Equity

$153M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$10M	+16.8%
Gross Profit	$12M	$10M	+16.8%
Operating Income	-$20M	-$12M	-67.7%
Net Income	-$15M	-$11M	-28.7%